Clinical trials: Celecoxib
Recurrent Neuroblastoma
Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma
Neuroblastoma is the second most frequent cause for death from cancer in childhood. Already one year after diagnosis of recurrence from high risk neuroblastoma, 75% of the patients experience further progression.
- Trial name
- METRO-NB2012 (NCT02641314)
- Testing
- metronomic therapy
- Where
- 8 sites in Germany
- Volunteers
- 18 people
- Sponsor
- University of Cologne
Pain, Postoperative, Surgery--Complications
Celecoxib vs. Acetaminophen/Codeine/Caffeine for Post-operative Analgesia in Rhinoplasty.
The primary aim of this study is to evaluate whether celecoxib (CELEBREX) is equivalent to acetaminophen-codeine-caffeine (TYLENOL# 3) for the management of pain after primary elective open septorhinoplasty with osteotomies.
- Conditions
- Pain, Postoperative, Surgery--Complications, Opioid Analgesic Adverse Reaction, Opioid Use
- Trial name
- NCT04259333
- Testing
- Celecoxib 200mg, Acetaminophen, Codeine Drug Combination
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Blake Raggio
Arthritis, Juvenile Rheumatoid
A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA
To study Celebrex versus naproxen to see if it decreases symptoms of juvenile arthritis such as pain and swelling.
- Trial name
- NCT00652925
- Testing
- Celecoxib, Naproxen
- Where
- 58 sites in United States, Belgium and 13 more
- Volunteers
- 225 people
- Sponsor
- Pfizer
Non Muscle Invasive Bladder Cancer
Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer
The treatment of non-muscle invasive bladder cancer (NMIBC) is problematic given the variable natural history of the disease. Although contemporary treatment options are limited, new targets and new approaches are under…
- Trial name
- NCT02343614
- Testing
- Celecoxib
- Volunteers
- 58 people
- Sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Scleroderma, Systemic, Sclerosis, Systemic
Pragmatic Clinical Trials in Scleroderma
Systemic Sclerosis (SSc) is an autoimmune connective tissue disease characterized by autoantibodies, fibrosis and microvascular injury and endothelial cell activation that results in vascular damage.
- Trial name
- PCTS (NCT03610217)
- Testing
- Interstitial lung disease induction algorithm, Pulmonary arterial hypertension algorithm, Raynaud's phenomenon algorithm
- Where
- Canada
- Volunteers
- 400 people
- Sponsor
- University of West London
Gynecologic Surgery, General Anesthesia
Long-term Follow-up of Bio-signals and Quality of Recovery Following Implementation of ERAS Based on the Mobile Application
The goal of this clinical trial is to evaluate the effect of an Enhanced Recovery After Surgery (ERAS) protocol in patients undergoing gynecologic laparoscopic or robotic surgery under general anesthesia.
- Trial name
- NCT07868952
- Testing
- Enhanced Recovery After Surgery, Usual Care
- Where
- South Korea
- Volunteers
- 350 people
- Sponsor
- Wonju Severance Christian Hospital
Cervical Cancer
Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00023660
- Testing
- celecoxib, cisplatin, fluorouracil
- Where
- 36 sites in United States
- Volunteers
- 84 people
- Sponsor
- Radiation Therapy Oncology Group
Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
This phase II trial tests how well the combination of celecoxib with durvalaumab and tremellimumab works in treating patients with hepatocellular cancer (liver cancer) that may have spread from where it first started to nearby…
- Conditions
- Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT07174570
- Testing
- Celecoxib, Durvalumab, Tremelimumab
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Emory University
Joint Pain, Knee Osteoarthritis
Efficacy and Safety of Celecoxib/Acetaminophen Versus Celecoxib for Diagnosed Osteoarthritis in Acute Exacerbation
This is a Phase III, longitudinal, multicenter, randomized, double-blind clinical trial designed to evaluate the efficacy and safety of a fixed-dose combination of celecoxib and acetaminophen compared to celecoxib monotherapy for…
- Conditions
- Joint Pain, Knee Osteoarthritis, Hip Osteoarthritis
- Trial name
- PRECEDENT (NCT06863636)
- Testing
- Celecoxib + Acetaminophen, Celecoxib
- Where
- Mexico
- Volunteers
- 231 people
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Malignant Childhood Neoplasm
Low Dose Chemotherapy Versus Best Supportive Care in Progressive Pediatric Malignancies
Many of the pediatric malignancies are not curable on progression on front line or 2nd line chemotherapy. Further therapy with conventional drugs imposes many side effects and decreases the QOL.
- Trial name
- NCT01858571
- Testing
- Low dose chemotherapy
- Where
- India
- Volunteers
- 108 people
- Sponsor
- All India Institute of Medical Sciences
Osteoarthritis
Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial I
The objective of this study is to evaluate the efficacy and safety of TDS-943 (topical diclofenac spray) compared to oral celecoxib and placebo in subjects with osteoarthritis of the knee.
- Trial name
- NCT00546507
- Testing
- TDS-943 (topical diclofenac sodium 4% spray), celecoxib
- Where
- 43 sites in United States
- Volunteers
- 650 people
- Sponsor
- Mika Pharma GmbH
Acute Pain
Efficacy and Safety in a Randomised Acute Pain Study of MR308: STARDOM2.
The MR308-3502 study is a multicenter double-blind, randomised, placebo- and active comparator-controlled study in female subjects to evaluate the efficacy and safety of MR308 with acute pain after TAH or STAH (total or subtotal…
- Trial name
- STARDOM2 (NCT03062644)
- Testing
- MR308
- Where
- 8 sites in Belarus, Bulgaria and 6 more
- Volunteers
- 1,138 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Breast Neoplasms
Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen
This is an open-label, multicenter, randomized (1:1 randomization ratio) study of either exemestane or exemestane plus celecoxib in postmenopausal women with ABC having progressed on tamoxifen.
- Trial name
- NCT00038103
- Testing
- Exemestane, Celecoxib + Exemestane
- Where
- 20 sites in United States, Belgium and 7 more
- Volunteers
- 111 people
- Sponsor
- Pfizer
Orthodontic Pain (D013850)
Efficacy of Selective COX-2 Inhibitors in Relieving Orthodontic Pain
The purpose of this study is to compare the efficacy of selective COX-2 inhibitors{ etoricoxib vs celecoxib )in relieving orthodontic pain , after initial bonding and arch wire insertion.
- Trial name
- EOSCOX2 (NCT07559682)
- Testing
- Celecoxib, Etoricoxib (Treatment Group)
- Where
- Pakistan
- Volunteers
- 150 people
- Sponsor
- Sharif Medical Research Center
Cancer of the Pharynx, Cancer of the Larynx
Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
There is no optimal treatment for patients with recurrent head and neck cancer after previous radiation. Chemotherapy alone is not curative and patients survive an average of only 6 to 10 months.
- Conditions
- Cancer of the Pharynx, Cancer of the Larynx, Cancer of the Neck, Paranasal Sinus Neoplasms
- Trial name
- NCT00970502
- Testing
- erlotinib + celecoxib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Johnny Kao
Cancer, Cachexia
A Feasibility Study of Multimodal Exercise/Nutrition/Anti-inflammatory Treatment for Cachexia - the Pre-MENAC Study
A multicentre, open, randomized phase II study comparing a multimodal intervention (oral nutritional supplements, celecoxib and physical exercise) for cachexia versus standard cancer care.
- Trial name
- NCT01419145
- Testing
- Multimodal intervention, Standard care
- Where
- 3 sites in Norway, United Kingdom
- Volunteers
- 46 people
- Sponsor
- Norwegian University of Science and Technology
Osteoarthritis, Knee
Efficacy and Safety of Celecoxib Versus Placebo in the Treatment of Patients With Osteoarthritis of the Knee Who Were Unresponsive to Naproxen and Ibuprofen
To compare the safety and efficacy of celecoxib versus placebo in the treatment of patients with knee osteoarthritis who were unresponsive to treatment with prescription strength naproxen and ibuprofen or who could not tolerate…
- Trial name
- NCT00640627
- Testing
- Celecoxib
- Where
- 30 sites in United States
- Volunteers
- 380 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Lung Cancer
Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Celecoxib may slow the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00030407
- Testing
- Celecoxib, Docetaxel
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Back Pain
Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain.
This study investigates if Celebrex is as effective as tramadol hydrochloride (Ultram) for patients with chronic low back pain, when administered over a 6-week period.
- Trial name
- NCT00290901
- Testing
- Tramadol Hydrochloride 50mg, Celebrex 200mg
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 754 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Precancerous Conditions
Chemoprevention of Oral Premalignant Lesions
Reduction in size and number of oral premalignant lesions
- Trial name
- NCT00036283
- Testing
- Celecoxib
- Where
- 7 sites in United States
- Volunteers
- 42 people
- Sponsor
- Pfizer